期刊
NATURE MEDICINE
卷 28, 期 6, 页码 1297-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-022-01792-5
关键词
-
资金
- European Health Emergency Preparedness and Response Authority (HERA)
- Institut Pasteur
- Region.le-de-France (DIM1Health)
- KU Leuven University
- Sciensano
- Urgence COVID-19 Fundraising Campaign of Institut Pasteur
- Fondation pour la Recherche Medicale (FRM)
- ANRS
- Vaccine Research Institute [ANR-10-LABX-77]
- Labex IBEID [ANR-10-LABX-62-IBEID]
- ANR/FRM Flash Covid PROTEO-SARS-CoV-2
- ANR Coronamito
- ANR IDISCOVR
- Region.le-de-France program DIM1Health
- Vaccine Research Institute
- Internal Funds KU Leuven [C14/18/094, 3M170314]
- Research FoundationFlanders (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen) [G0E1420N, G098321N]
- COVID-19 research grant of 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders [G0H4420N]
- 'Fonds Wetenschappelijk Onderzoek'/Research Foundation Flanders [G0H4420N]
- INCEPTION program (Investissements d'Avenir grant) [ANR-16-CONV-0005]
- [ANR10-INSB-04-01]
There are differences in neutralizing activity of therapeutic antibodies against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, and immunocompromised individuals treated with antibodies show elevated antibody levels but reduced neutralization against Omicron. Breakthrough infections with the Omicron variant are observed in some immunocompromised individuals despite antibody treatment.
Therapeutic antibodies, and sera from immunocompromised individuals prophylactically treated with therapeutic antibodies, differ in neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, which could have implications for pre-exposure and post-exposure treatment. The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 mutations in its spike. In this study, we first compared the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs). In contrast to BA.1, BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. We then analyzed sera from 29 immunocompromised individuals up to 1 month after administration of Ronapreve (casirivimab and imdevimab) and/or Evusheld (cilgavimab and tixagevimab) antibody cocktails. All treated individuals displayed elevated antibody levels in their sera, which efficiently neutralized the Delta variant. Sera from Ronapreve recipients did not neutralize BA.1 and weakly inhibited BA.2. Neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 Evusheld recipients, respectively. As compared to the Delta variant, neutralizing titers were more markedly decreased against BA.1 (344-fold) than BA.2 (nine-fold). We further report four breakthrough Omicron infections among the 29 individuals, indicating that antibody treatment did not fully prevent infection. Collectively, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron neutralizing activity of Ronapreve and, to a lesser extent, that of Evusheld is reduced in patients' sera.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据